At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 477 enrolled
Drug / intervention
insulin detemir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Insulin Detemir Combined With OAD Versus Insulin NPH Combined With OAD in Type 2 Mellitus
In Brief
A Phase 3 clinical trial evaluating insulin detemir and insulin NPH for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 477 participants across 62 sites in 10 countries.
Detailed Summary
This trial is conducted in Europe. The aim of this trial is to investigate the safety and efficacy of insulin detemir combined with oral anti-diabetic drugs (OADs) versus insulin NPH combined with oral anti-diabetic drugs (OADs) in Type 2 mellitus not well controlled on current therapy on blood glucose control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesBelgium, Croatia, Denmark, France, North Macedonia, Norway, Poland, Russia, Slovakia, Sweden
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2003
Primary CompletionJan 2004
First PostedJan 2008
TodayJul 2026
First PostedJan 30, 2008
Enrollment StartMar 1, 2003
Primary CompletionJan 1, 2004
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.4 years ago
Interventions
insulin detemirdrug
insulin NPHdrug